Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia
Open Access
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-9
- https://doi.org/10.1186/s12885-021-07897-3
Abstract
Transplantation-related mortality (TRM) is a major obstacle in allogeneic hematopoietic cell transplantation (allo-HCT). Approximately 60–80% of TRM occurs early, within 100 days of transplantation. This was a nationwide population cohort study involving 5395 patients with acute leukemia who underwent allo-HCT between 2003 and 2015. Patient data were collected from the Korean National Health Insurance Service database. We investigated the cumulative incidence rates (CIRs) of early TRM at 50 and 100 days. The CIRs of early TRM at 50 and 100 days were 2.9 and 8.3%, respectively. There was no decrease in the CIRs of early TRM over time. The early mortality was significantly higher in patients with more than 9 months between the diagnosis and transplantation (CIRs of TRM at 50, 100 days; 6.0, 13.2%), previous transplantations (CIRs of TRM at 50, 100 days; 9.4, 17.2%), and cord blood transplantation (CIRs of TRM at 50, 100 days; 6.1, 8.3%). The early TRM was significantly lower in patients who received iron chelation before transplantation (CIRs of TRM at 50, 100 days; 0.3, 1.8%). In conclusion, the overall CIR of early TRM was less than 10%. The predictable factors for early TRM included age, time from diagnosis to transplantation, the number of prior transplantations, the graft source, and previous iron chelation therapy.Keywords
This publication has 31 references indexed in Scilit:
- What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?Bone Marrow Transplantation, 2019
- Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell TransplantationTurkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2017
- Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante HematopoyeticoTransplantation and Cellular Therapy, 2016
- Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center StudyTransplantation and Cellular Therapy, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2010
- Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2008
- Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersBlood, 2007
- Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.2004
- Non‐transferrin‐bound iron during allogeneic stem cell transplantationBritish Journal of Haematology, 2001